TEVA PHARMACEUTICAL INDUSTRIES LTD
Teva Pharmaceutical Industries (NYSE:TEVA) moved its anti-IL-15 antibody TEV-408 into a Phase 2b trial for nonsegmental vitiligo after Phase 1b data showed repigmentation and a favorable safety profile, according to the article. TEVA shares closed at $36.77, up 16.51% over 30 days, with 1-year total return of 105.88%. The piece cites fair value at $40.90 and revenue above $17.3b.
A public advisory says two lots of Teva pregabalin 150 mg capsules were recalled due to possible cross-contamination with sertraline. The notice advises patients to stop the product and seek emergency care for serious allergic reactions, and to consult a clinician before stopping otherwise. Customers should return the recalled items to the pharmacy for replacement or disposal.
Moody’s Ratings upgraded Teva Pharmaceutical Industries (NYSE:TEVA) to investment grade, raising its issuer rating to Baa3 from Ba1 and changing the outlook to stable from positive. Moody’s cited branded sales growth, pipeline expansion, and deleveraging. It expects gross debt/EBITDA to fall below 3.75x, and forecasts about $2.0B free cash flow over 12 months.
Over the past 7 days, alphai's AI scored 5 news stories mentioning TEVA (TEVA PHARMACEUTICAL INDUSTRIES LTD). Coverage has skewed bullish: 3 bullish, 1 neutral, and 1 bearish.
Recent TEVA coverage spans financial news, regulation and technology.
In the last 30 days, TEVA insiders filed 3 SEC Form 4 transactions — no purchases and 3 sales ($1.3M). The most active reporter was Zaks Tal Zvi with 1 filing. 67% of those filings were made under pre-arranged Rule 10b5-1 plans.
The Phase 2b initiation is a pipeline catalyst that can re-rate TEVA’s vitiligo franchise expectations, but the article frames it as valuation debate rather than new financial guidance.
Recall risk can pressure near-term sales, trigger replacement costs, and raise liability exposure, though the article provides no financial magnitude.
Investment-grade upgrade tied to deleveraging and leverage targets can improve funding conditions and reduce credit risk premium.
An investment-grade upgrade should improve Teva's funding profile and index eligibility, supporting lower credit risk and potentially tighter spreads.
The motion is a procedural attempt to limit jury exposure to Israel-linked controversy, which could affect trial dynamics and perceived credibility.
alphai scores every news story that mentions TEVA with an AI model for sentiment and relevance, and aggregates insider trades from TEVA PHARMACEUTICAL INDUSTRIES LTD's SEC EDGAR Form 4 filings. Figures refresh continuously.
Teva Pharmaceutical Industries (NYSE:TEVA) moved its anti-IL-15 antibody TEV-408 into a Phase 2b trial for nonsegmental vitiligo after Phase 1b data showed repigmentation and a favorable safety profile, according to the article. TEVA shares closed at $36.77, up 16.51% over 30 days, with 1-year total return of 105.88%. The piece cites fair value at $40.90 and revenue above $17.3b.
7 min readA public advisory says two lots of Teva pregabalin 150 mg capsules were recalled due to possible cross-contamination with sertraline. The notice advises patients to stop the product and seek emergency care for serious allergic reactions, and to consult a clinician before stopping otherwise. Customers should return the recalled items to the pharmacy for replacement or disposal.
1 min readMoody’s Ratings upgraded Teva Pharmaceutical Industries (NYSE:TEVA) to investment grade, raising its issuer rating to Baa3 from Ba1 and changing the outlook to stable from positive. Moody’s cited branded sales growth, pipeline expansion, and deleveraging. It expects gross debt/EBITDA to fall below 3.75x, and forecasts about $2.0B free cash flow over 12 months.
3 min readTeva Pharmaceutical Industries (NYSE: TEVA) said Moody’s upgraded its corporate credit rating to Baa3 from Ba1 with a stable outlook. Moody’s cited execution of Teva’s Pivot to Growth strategy, including growth products, pipeline expansion, and continued debt reduction supported by earnings growth, plus improving margins and free cash flow. Teva expects further debt reduction over 12 to 18 months.
2 min readIsraeli drugmaker Teva Pharmaceuticals asked a U.S. judge to bar insurer Humana from telling jurors Teva is Israeli in a generic drug price-fixing trial. Teva said its corporate origin is irrelevant to alleged price inflation of drugs including baclofen and propranolol. The trial is set to start Sept. 15 in Philadelphia.
4 min readTeva Pharmaceutical Industries asked a U.S. judge to bar Humana’s lawsuit from telling jurors that Teva is Israeli-based, saying the references could be prejudicial and irrelevant. The case, Humana Inc. v. Actavis Elizabeth, LLC, et al., is set for trial Sept. 15 in Philadelphia federal court. Teva denies price-fixing allegations.
3 min readTeva (TEVA) reported Q2 2026 revenue of $4.1B, down 1% year over year due to lower U.S. generic sales. Innovative brands rose, including AUSTEDO $696M (+40%), AJOVY $244M (+56%), and UZEDY $77M (+43%). Non-GAAP EPS was $0.02 and free cash flow was $622M (+31%). 2026 revenue guidance was raised to $16.5B-$16.85B; net debt was $12.9B (2.8x).
10 min readIn Humana Inc. v. Actavis Elizabeth LLC, et al. (EDPA July 27, 2026), a judge held that facts admitted in a DOJ Deferred Prosecution Agreement are binding in follow-on civil antitrust cases. The ruling relied on Teva’s Rule 36 admissions quoting its DPA Statement of Facts, granting partial summary judgment on a Section 1 per se price-fixing claim.
6 min readTeva Pharmaceuticals USA asked a U.S. federal judge to bar references to its Israeli identity in an upcoming antitrust trial. In a motion in Pennsylvania, Teva said its nationality and ties to Israel are irrelevant to allegations of generic drug price-fixing and market allocation. Teva cited Pew polling showing 60% unfavorable views of Israel in the U.S. and argued Israel-related references could bias jurors.
2 min readHughes Eric A (See "Remarks") sold 25,578 shares of TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) at $34.88 ($0.89M total) on 2026-08-03 under a Rule 10b5-1 trading plan.
1 min read
